The relationship between platinum drug resistance and epithelial-mesenchymal transition

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Platinum-based chemotherapy is a cornerstone in treating various cancers.
• Frequent development of drug resistance limits the long-term efficacy of platinum drugs.
• Predictive biomarkers for cellular response to platinum drugs remain elusive in specific tumor types.

Purpose of the Study:

• To review the complex relationship between epithelial-mesenchymal transition (EMT) and platinum drug resistance.
• To elucidate the molecular mechanisms and signaling networks connecting EMT and platinum resistance.
• To identify potential therapeutic targets for overcoming platinum resistance in cancer.

Main Methods:

• Literature review of existing studies on platinum drug resistance and EMT.
• Analysis of molecular mechanisms, including transcription factors and miRNAs, involved in both processes.
• Synthesis of current knowledge on signaling pathways regulating EMT and drug resistance.

Main Results:

• Epithelial-mesenchymal transition (EMT), a phenotype associated with cancer invasion and metastasis, is increasingly linked to chemoresistance.
• Shared molecular players, such as SNAIL, TWIST, ZEB transcription factors, and the miRNA-200 family, are implicated in both EMT and platinum resistance.
• The intricate signaling networks governing these phenomena are complex and not fully understood.

Conclusions:

• Understanding the interplay between EMT and platinum resistance is crucial for improving cancer treatment outcomes.
• Identifying molecules involved in both EMT and platinum resistance offers promising avenues for novel therapeutic strategies.
• Further research into these molecular targets may lead to more effective treatments for platinum-resistant cancers.